Mulholland M, Kritikou E, Katra P, Nilsson J, Björkbacka H, Lichtman AH, Rodriguez A, Engelbertsen D
LAG3 Regulates T-cell Activation and Plaque Infiltration in Atherosclerotic Mice
JACC: CardioOncology. 2022;4(5):635-645.
In the originally published version of this study, the wrong images were selected to illustrate representative plaque size comparing anti-LAG3 or control IgG treatment groups (Figure 2F). The authors have now corrected this error. Importantly, the original quantification of plaque size in Figure 2F is still accurate, and this error does in no way affect our interpretation of the data or the paper as a whole.
Figure 2.
Anti-LAG3 Treatment Expands T Helper 1 Cells and Regulatory T Cells
(A) Low-density lipoprotein knockout mice (Ldlr-/-) were fed an HCD for 10 weeks and injected with 0.2 mg isotype control (ctrl) immunoglobulin G (IgG) (n = 12) or anti-LAG3 (n = 12) twice a week for 4 weeks. (B, C) CD4+ CD44hiCD62L- effector cells or CD4+CD25+FoxP3+ regulatory T cells (Tregs) were quantified in spleen (SPL) or aortic lymph nodes (aLN). (D) Levels of the proliferation marker Ki67 were measured in CD4+ conventional T cells (FoxP3- Tconv) or Tregs (FoxP3+ Tregs) in SPL. (E) Levels of interferon (IFN)-γ–producing T helper 1 (Th1) cells in SPL. (F) Histological quantification of subvalvular plaque area and representative Oil Red O–stained images. Scale bar = 100 μm. An unpaired t test was used to analyze normally distributed data and a Mann-Whitney U test was used for non-normally distributed data. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Abbreviations as in Figure 1.
The authors apologize for this error.
The online version of this paper will be corrected to reflect this change.